Interview with Piero Di Lorenzo.
The Italian vaccine by IRBM: one of the first in race
“It’s a big match, hopefully no favorites in Europe”. Piero Di Lorenzo, President and CEO of IRBM, so describes the current challenge to find a coronavirus vaccine. Then he adds: “politics has to talk with Angela Merkel, Boris Johnson and the other governments, invest money and prevent Italy from being shattered […]”. The Italian IRBM is starting clinical trial in the end of April. This experimental vaccine is the outcome of two expertise: the Jenner Institute skills in coronavirus and the IRBM ones in adenovirus. Di Lorenzo also speaks about the manufacturing, the funding and the expected time to approve this vaccine.
Article by Maria Elena Capitanio published on Panorama – 22/04/2020